Prognostic factors in adrenocortical carcinoma: data from a large Polish series

• Published in: Polskie archiwum medycyny wewne̦trznej Vol. 128; no. 6; pp. 371 - 378
• Main Authors: Nowak, Karolina M, Samsel, Radosław, Cichocki, Andrzej, Ambroziak, Urszula, Roszkowska-Purska, Katarzyna, Łebek-Szatańska, Agnieszka, Koperski, Łukasz, Otto, Maciej, Zgliczyński, Wojciech, Papierska, Lucyna
• Format: Journal Article
• Language: English
• Published: Poland 30.06.2018
• Subjects: Adrenocortical Carcinoma - drug therapy; Adrenocortical Carcinoma - surgery; Adrenocortical Carcinoma - therapy; Adult; Aged; Female; Humans; Male; Middle Aged; Mitotane - therapeutic use; Mitotic Index; Poland; Prognosis; Retrospective Studies; Survival Rate; Poland
• ISSN: 1897-9483; 1897-9483
• DOI: 10.20452/pamw.4260

Introduction Adrenocortical carcinoma (ACC) is a rare malignancy, associated with poor outcome and few therapeutic options. Despite increasing attention, the knowledge about the clinical course and treatment of these tumors is limited. Objectives Survival rates in ACC are still low and the percentage of relapse is high. Thus, it is crucial to identify the prognostic factors of overall survival (OS) and recurrence‑free survival (RFS). Patients and methods This was a retrospective analysis of 66 patients diagnosed with ACC between 2002 and 2015. Results The median OS was 43.5 months, 78.19 months for stage I + II, 22.95 months for stage III, and 19.54 months for stage IV ACC. Older age, stage IV ACC, margin status R2, and no mitotane treatment were associated with poor OS. Low Ki67 and mitotic indices were related to improved OS in a univariate analysis. The median RFS was 101.1 months. Disease recurrence after potentially curative surgery was reported in 1 patient (25%) with stage I, 12 patients (46%) with stage II, and 9 patients (45%) with stage III ACC. Male sex and no mitotane treatment were associated with a reduced RFS in a multivariate analysis and higher Ki67 and mitotic indices in the univariate analysis. Conclusions Ki67 and mitotic indices should be considered as prognostic factors when planning the adjuvant treatment of ACC. Mitotane treatment may be independently associated with better outcomes regardless of the tumor stage.